Optinose_logo_RGB.png
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
November 22, 2023 09:00 ET | Optinose, Inc.
YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
November 09, 2023 07:00 ET | Optinose, Inc.
Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency as SG&A and R&D...
Optinose_logo_RGB.png
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
October 27, 2023 08:00 ET | Optinose, Inc.
YARDLEY, Pa., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose to Present at the 2023 Cantor Global Healthcare Conference
September 22, 2023 09:01 ET | Optinose, Inc.
YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
August 10, 2023 07:00 ET | Optinose, Inc.
Company reports second quarter 2023 XHANCE net revenue of $19.5 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency in the first half of 2023...
Optinose_logo_RGB.png
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
July 27, 2023 07:00 ET | Optinose, Inc.
Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE net revenue guidance on August 10 ...
Optinose_logo_RGB.png
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2023 16:08 ET | Optinose, Inc.
YARDLEY, Pa., June 16, 2023 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose_logo_RGB.png
Optinose to Present at the Jefferies Healthcare Conference
June 02, 2023 13:00 ET | Optinose, Inc.
YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
May 11, 2023 07:00 ET | Optinose, Inc.
Strong progress towards strategic objectives including acceptance of sNDA for review and prioritization of potential launch of XHANCE as first drug approved to treat chronic rhinosinusitis Company...
Optinose_logo_RGB.png
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
May 04, 2023 07:00 ET | Optinose, Inc.
The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If...